期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 55, 期 1, 页码 437-448出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm2013198
关键词
-
资金
- NIDCR NIH HHS [R01 DE007389] Funding Source: Medline
Dinucleoside polyphosphates, NpnN', exert their physiological effects via P2 receptors (P2Rs). NpnN' are attractive drug candidates as they offer better stability and specificity compared to nucleotides, the most common P2R ligands. To further improve the agonist properties of NpnN', we synthesized novel isosters of dinucleoside polyphosphates where N and N' are A or U and where the P alpha or P beta phosphate groups are replaced by boranophosphate, denoted as Np-n(alpha-B)N' or Np-n(beta-B)N' (n = 3, 4), respectively. The potency of Np-n(alpha/beta-B)N'. analogues was evaluated at tP2Y(1), hP2Y(2), hP2Y(4), and rP2Y(6) receptors. The most potent P2Y(1)R and P2Y(6)R agonists were the Up(4)(beta-B)A (A isomer, EC50 of 0.5 mu M vs 0.004 mu M for 2-SMe-ADP) and Up(3)(alpha-B)U (B isomer, EC50 of 0.3 mu M vs 0.2 mu M for UDP), respectively. The receptor subtype selectivity is controlled by the position of the borano moiety on the NpnN' polyphosphate chain and the type of the nucleobase. In addition, Np-n(alpha/beta-B)N' proved similar to 22-fold more resistant to hydrolysis by e-NPP1, as compared to the corresponding NpnN' analogues. In summary, Up(4)(beta-B)A and Up(3)(alpha-B)U are potent, stable, and highly selective P2Y(1) and P2Y(6) receptor agonists, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据